GB8430346D0
(en)
*
|
1984-11-30 |
1985-01-09 |
Reckitt & Colmann Prod Ltd |
Analgesic compositions
|
EP0236477B1
(fr)
*
|
1985-09-06 |
1993-01-20 |
Baker Norton Pharmaceuticals, Inc. |
Utilisation de méthylène-6 désoxy-6, N-cyclopropyl-méthyl-hydroxy-14-dihydronormorphine
|
GB8608818D0
(en)
*
|
1986-04-11 |
1986-05-14 |
Reckitt & Colmann Prod Ltd |
Pharmaceutical compositions
|
US4673679A
(en)
*
|
1986-05-14 |
1987-06-16 |
E. I. Du Pont De Nemours And Company |
Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
|
JPS62298530A
(ja)
*
|
1986-06-16 |
1987-12-25 |
Otsuka Pharmaceut Co Ltd |
坐薬用医薬組成物
|
US4769372A
(en)
*
|
1986-06-18 |
1988-09-06 |
The Rockefeller University |
Method of treating patients suffering from chronic pain or chronic cough
|
US5236714A
(en)
*
|
1988-11-01 |
1993-08-17 |
Alza Corporation |
Abusable substance dosage form having reduced abuse potential
|
US5069909A
(en)
*
|
1990-06-20 |
1991-12-03 |
Cygnus Therapeutic Systems |
Transdermal administration of buprenorphine
|
US6096756A
(en)
*
|
1992-09-21 |
2000-08-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
US5512578A
(en)
*
|
1992-09-21 |
1996-04-30 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
|
US5376662A
(en)
*
|
1993-12-08 |
1994-12-27 |
Ockert; David M. |
Method of attenuating nerve injury induced pain
|
US5552406A
(en)
*
|
1994-06-17 |
1996-09-03 |
The Mclean Hospital Corporation |
Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
|
US5968547A
(en)
*
|
1997-02-24 |
1999-10-19 |
Euro-Celtique, S.A. |
Method of providing sustained analgesia with buprenorphine
|
EP0913152B1
(fr)
*
|
1997-11-03 |
2001-12-19 |
Stada Arzneimittel Ag |
Composition stabilisée d'une combinaison de substances actives comprenant de la naloxone et un opioide analgésique
|
DE29720448U1
(de)
*
|
1997-11-03 |
1998-01-15 |
Stada R + D GmbH, 61118 Bad Vilbel |
Stabilisiertes Kombinationsarzneimittel
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
BR9813827A
(pt)
*
|
1997-12-22 |
2000-10-10 |
Euro Celtique Sa |
Analgésico opióide aplicável em mamìferos e método para impedir o uso oral abusivo de uma formulação opióide oral
|
JP2001526229A
(ja)
*
|
1997-12-22 |
2001-12-18 |
ユーロ−セルティーク,エス.エイ. |
オピオイド投薬剤形の乱用を防止する方法
|
US6007841A
(en)
*
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
SE9803240D0
(sv)
|
1998-09-24 |
1998-09-24 |
Diabact Ab |
A pharmaceutical composition having a rapid action
|
SE9803239D0
(sv)
*
|
1998-09-24 |
1998-09-24 |
Diabact Ab |
Composition for the treatment of acute pain
|
US7087215B2
(en)
*
|
1998-12-21 |
2006-08-08 |
Generex Pharmaceuticals Incorporated |
Methods of administering and enhancing absorption of pharmaceutical agents
|
US6849263B2
(en)
*
|
1998-12-21 |
2005-02-01 |
Generex Pharmaceutical Incorporated |
Pharmaceutical compositions for buccal delivery of pain relief medications
|
US6835194B2
(en)
|
1999-03-18 |
2004-12-28 |
Durect Corporation |
Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
|
US6541021B1
(en)
*
|
1999-03-18 |
2003-04-01 |
Durect Corporation |
Devices and methods for pain management
|
US6495155B1
(en)
*
|
1999-08-27 |
2002-12-17 |
Southern Research Institute |
Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances
|
AR031682A1
(es)
|
1999-11-19 |
2003-10-01 |
Reckitt Benckiser Helthcare Uk |
Composiciones farmaceuticas
|
ES2278647T3
(es)
*
|
1999-11-29 |
2007-08-16 |
Adolor Corporation |
Nuevos procedimientos y composiciones que comprenden opioides y antagonistas de opioides.
|
WO2001040269A2
(fr)
*
|
1999-11-30 |
2001-06-07 |
Corixa Corporation |
Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
|
MXPA02007686A
(es)
|
2000-02-08 |
2003-03-27 |
Euro Celtique Sa |
Formulaciones orales y resistentes a intervenciones de agonistas opioides..
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
US7074803B2
(en)
*
|
2001-03-02 |
2006-07-11 |
Durect Corporation |
Opioid formulations
|
US20040024004A1
(en)
*
|
2001-05-04 |
2004-02-05 |
Sherman Barry M. |
Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
|
ATE493130T1
(de)
|
2001-05-11 |
2011-01-15 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
WO2003002100A1
(fr)
*
|
2001-06-26 |
2003-01-09 |
Farrell John J |
Systeme d'administration de narcotique inviolable
|
ATE359077T1
(de)
*
|
2001-07-06 |
2007-05-15 |
Endo Pharmaceuticals Inc |
Orale gabe von 6-hydroxy-oxymorphon als analgetikum
|
PL208484B1
(pl)
*
|
2001-07-06 |
2011-05-31 |
Penwest Pharmaceuticals Company |
Sposoby wytwarzania preparatów oksymorfonu o przedłużonym uwalnianiu
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
WO2003006980A1
(fr)
*
|
2001-07-13 |
2003-01-23 |
Arkray, Inc. |
Appareil d'analyse, corps a element de perçage integralement installe pour un dispositif de mesure de la temperature associe a l'appareil d'analyse, et appareil de prelevement de liquide organique
|
ES2319620T3
(es)
*
|
2001-07-18 |
2009-05-11 |
Euro-Celtique S.A. |
Conbinaciones farmaceuticas de oxicodona y naloxona.
|
US20030157168A1
(en)
*
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US7842307B2
(en)
|
2001-08-06 |
2010-11-30 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
|
SI1414451T1
(sl)
|
2001-08-06 |
2009-10-31 |
Euro Celtique Sa |
Formulacije opioidnega agonista s sproščanja sposobnim in sekvestriranim antagonistom
|
WO2003026743A2
(fr)
*
|
2001-09-26 |
2003-04-03 |
Penwest Pharmaceuticals Company |
Formulations d'opioides presentant un potentiel reduit pour des utilisations abusives
|
US8900497B2
(en)
|
2001-10-12 |
2014-12-02 |
Monosol Rx, Llc |
Process for making a film having a substantially uniform distribution of components
|
US7357891B2
(en)
|
2001-10-12 |
2008-04-15 |
Monosol Rx, Llc |
Process for making an ingestible film
|
US20190328679A1
(en)
|
2001-10-12 |
2019-10-31 |
Aquestive Therapeutics, Inc. |
Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
|
US8765167B2
(en)
|
2001-10-12 |
2014-07-01 |
Monosol Rx, Llc |
Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
|
US20110033542A1
(en)
|
2009-08-07 |
2011-02-10 |
Monosol Rx, Llc |
Sublingual and buccal film compositions
|
US20070281003A1
(en)
|
2001-10-12 |
2007-12-06 |
Fuisz Richard C |
Polymer-Based Films and Drug Delivery Systems Made Therefrom
|
US8603514B2
(en)
|
2002-04-11 |
2013-12-10 |
Monosol Rx, Llc |
Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
|
US8900498B2
(en)
|
2001-10-12 |
2014-12-02 |
Monosol Rx, Llc |
Process for manufacturing a resulting multi-layer pharmaceutical film
|
US20140271788A1
(en)
|
2013-03-15 |
2014-09-18 |
Monosol Rx, Llc |
Sublingual and buccal film compositions
|
US11207805B2
(en)
|
2001-10-12 |
2021-12-28 |
Aquestive Therapeutics, Inc. |
Process for manufacturing a resulting pharmaceutical film
|
US10285910B2
(en)
|
2001-10-12 |
2019-05-14 |
Aquestive Therapeutics, Inc. |
Sublingual and buccal film compositions
|
AP2397A
(en)
|
2002-04-05 |
2012-04-23 |
Euro Celtique Sa |
Matrix for sustained, invariant and independent release of active compounds.
|
US7041320B1
(en)
|
2002-05-31 |
2006-05-09 |
Biotek, Inc. |
High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
|
US7157102B1
(en)
|
2002-05-31 |
2007-01-02 |
Biotek, Inc. |
Multi-layered microcapsules and method of preparing same
|
SI2561860T1
(en)
*
|
2002-05-31 |
2018-05-31 |
Titan Pharmaceuticals, Inc. |
An implantable polymeric device for prolonged release of buprenorphine
|
EP2422772A3
(fr)
*
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Séquestration de sous-unité et compositions et procédés associés
|
US20040102476A1
(en)
*
|
2002-11-25 |
2004-05-27 |
Chan Tai Wah |
High concentration formulations of opioids and opioid derivatives
|
AU2003297074A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Euro-Celtique S.A. |
Transdermal buprenorphine to treat pain in sickle cell crisis
|
PT1610791E
(pt)
*
|
2003-03-31 |
2011-05-23 |
Titan Pharmaceuticals Inc |
Dispositivo polim?rico implant?vel para liberta??o sustentada de agonista da dopamina
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
EP1613324A2
(fr)
*
|
2003-04-14 |
2006-01-11 |
Pain Therapeutics, Inc. |
Procedes de traitement des douleurs comprenant des antagonistes opioides
|
JP5501553B2
(ja)
|
2003-04-21 |
2014-05-21 |
ユーロ−セルティーク エス.エイ. |
同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
US8790689B2
(en)
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
US8778382B2
(en)
*
|
2003-04-30 |
2014-07-15 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
EP2112920B1
(fr)
|
2003-06-26 |
2018-07-25 |
Intellipharmaceutics Corp. |
Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
|
US20060009478A1
(en)
*
|
2003-10-15 |
2006-01-12 |
Nadav Friedmann |
Methods for the treatment of back pain
|
US8883204B2
(en)
|
2003-12-09 |
2014-11-11 |
Purdue Pharma L.P. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
JP4917893B2
(ja)
*
|
2003-12-09 |
2012-04-18 |
ユーロ−セルティーク エス.エイ. |
作用薬及び逆作用薬を含有する不正使用防止共押出剤型、及びその製造方法
|
CA2557839C
(fr)
*
|
2004-03-30 |
2011-05-10 |
Euro-Celtique S.A. |
Forme posologique resistant aux violations, comprenant un absorbant et un agent adverse
|
EP1604667A1
(fr)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioides pour le traitement des impatiences des membres inférieurs
|
EP1604666A1
(fr)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioides pour le traitement de la bronchopneumopathie chronique obstructive
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
US9415034B2
(en)
*
|
2005-01-05 |
2016-08-16 |
National Defense Medical Center |
Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
|
EP2289491A1
(fr)
*
|
2005-01-28 |
2011-03-02 |
Euro-Celtique S.A. |
Medicament resistant contre l' alcohol
|
EP1695700A1
(fr)
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Forme posologique contenant de l'oxycodone et de la naloxone
|
EP1702558A1
(fr)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Procédé et dispositif pour évaluer la fonction de l'activité intestinale
|
US20060281775A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Applied Pharmacy Services, Inc. |
Two-component pharmaceutical composition for the treatment of pain
|
WO2007056142A2
(fr)
*
|
2005-11-02 |
2007-05-18 |
Theraquest Biosciences, Llc |
Procedes de prevention du syndrome serotoninergique et compositions utilisees a cette fin
|
WO2007087452A2
(fr)
*
|
2006-01-27 |
2007-08-02 |
Theraquest Biosciences, Llc |
Formulations à libération prolongée empêchant l'usage abusif et méthodes d'utilisation de celles-ci
|
US9125833B2
(en)
*
|
2005-11-02 |
2015-09-08 |
Relmada Therapeutics, Inc. |
Multimodal abuse resistant and extended release opioid formulations
|
US8329744B2
(en)
*
|
2005-11-02 |
2012-12-11 |
Relmada Therapeutics, Inc. |
Methods of preventing the serotonin syndrome and compositions for use thereof
|
EP1968539A2
(fr)
*
|
2005-12-13 |
2008-09-17 |
Biodelivery Sciences International, Inc. |
Dispositif resistant aux abus pour l'administration transmucosale de medicaments
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US9066847B2
(en)
|
2007-01-05 |
2015-06-30 |
Aceirx Pharmaceuticals, Inc. |
Storage and dispensing devices for administration of oral transmucosal dosage forms
|
US8865743B2
(en)
|
2006-01-06 |
2014-10-21 |
Acelrx Pharmaceuticals, Inc. |
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
|
US8535714B2
(en)
|
2006-01-06 |
2013-09-17 |
Acelrx Pharmaceuticals, Inc. |
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
|
US8252329B2
(en)
*
|
2007-01-05 |
2012-08-28 |
Acelrx Pharmaceuticals, Inc. |
Bioadhesive drug formulations for oral transmucosal delivery
|
US8753308B2
(en)
|
2006-01-06 |
2014-06-17 |
Acelrx Pharmaceuticals, Inc. |
Methods for administering small volume oral transmucosal dosage forms using a dispensing device
|
US8252328B2
(en)
|
2006-01-06 |
2012-08-28 |
Acelrx Pharmaceuticals, Inc. |
Bioadhesive drug formulations for oral transmucosal delivery
|
US8202535B2
(en)
*
|
2006-01-06 |
2012-06-19 |
Acelrx Pharmaceuticals, Inc. |
Small-volume oral transmucosal dosage forms
|
US9289583B2
(en)
*
|
2006-01-06 |
2016-03-22 |
Acelrx Pharmaceuticals, Inc. |
Methods for administering small volume oral transmucosal dosage forms using a dispensing device
|
US8357114B2
(en)
*
|
2006-01-06 |
2013-01-22 |
Acelrx Pharmaceuticals, Inc. |
Drug dispensing device with flexible push rod
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
CN101453993A
(zh)
*
|
2006-04-03 |
2009-06-10 |
伊萨·奥迪迪 |
含有机溶胶涂层的受控释放递送物件
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
PL2526932T3
(pl)
*
|
2006-06-19 |
2017-12-29 |
Alpharma Pharmaceuticals Llc |
Kompozycja farmaceutyczna
|
EP3067044B1
(fr)
|
2006-07-21 |
2019-03-27 |
BioDelivery Sciences International, Inc. |
Dispositifs d'administration transmuqueuse avec absorption accrue
|
EP1897543A1
(fr)
|
2006-08-30 |
2008-03-12 |
Euro-Celtique S.A. |
Gaufre de buprénorphine pour la thérapie de substitution
|
SI2101740T1
(sl)
|
2006-12-04 |
2014-03-31 |
Orexo Ab |
Nov nezlorabljiv farmacevtski sestavek, obsegajoč opiode
|
GB2447015A
(en)
*
|
2007-03-01 |
2008-09-03 |
Reckitt Benckiser Healthcare |
Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
|
GB2447016A
(en)
*
|
2007-03-01 |
2008-09-03 |
Reckitt Benckiser Healthcare |
Buprenorphine/naloxone compositions
|
WO2008115811A2
(fr)
*
|
2007-03-16 |
2008-09-25 |
Endo Pharmaceuticals, Inc. |
Systèmes et procédés d'élimination de forme d'administration transdermique
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
ES2635137T3
(es)
*
|
2007-08-07 |
2017-10-02 |
Acelrx Pharmaceuticals, Inc. |
Formas de dosificación oral transmucosal que comprenden sufentanilo y triazolam
|
US7748244B2
(en)
*
|
2007-09-14 |
2010-07-06 |
Schlage Lock Company |
Deadbolt lock assembly
|
US20100266645A1
(en)
*
|
2007-12-17 |
2010-10-21 |
Alfred Liang |
Pharmaceutical compositions
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
KR20130105935A
(ko)
*
|
2008-07-07 |
2013-09-26 |
유로-셀티큐 에스.에이. |
요폐의 치료를 위한 아편유사제 길항제의 용도
|
US8945592B2
(en)
*
|
2008-11-21 |
2015-02-03 |
Acelrx Pharmaceuticals, Inc. |
Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
|
PL2405915T3
(pl)
|
2009-03-10 |
2019-05-31 |
Euro Celtique Sa |
Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
|
WO2010107761A1
(fr)
|
2009-03-18 |
2010-09-23 |
Acelrx Pharmaceuticals, Inc. |
Dispositifs de stockage et de distribution améliorés pour l'administration de formes posologiques transmucosales orales
|
US8475832B2
(en)
|
2009-08-07 |
2013-07-02 |
Rb Pharmaceuticals Limited |
Sublingual and buccal film compositions
|
US20110091544A1
(en)
*
|
2009-10-16 |
2011-04-21 |
Acelrx Pharmaceuticals, Inc. |
Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
|
EP2552425B1
(fr)
*
|
2010-04-02 |
2016-07-27 |
Buzzz Pharmaceuticals Limited |
Formulations transdermiques inviolables d'agonistes et d'agonistes-antagonistes d'opiacés
|
US9149959B2
(en)
|
2010-10-22 |
2015-10-06 |
Monosol Rx, Llc |
Manufacturing of small film strips
|
CA3119258A1
(fr)
|
2011-08-18 |
2013-02-21 |
Biodelivery Sciences International, Inc. |
Dispositifs mucoadhesifs anti-abus destines a administrer de la buprenorphine
|
PT2915525T
(pt)
|
2011-09-19 |
2021-09-15 |
Orexo Ab |
Comprimidos sublinguais resistentes a abuso que compreendem buprenorfina e naloxona
|
DK3153171T3
(en)
|
2011-12-15 |
2018-11-19 |
Alkermes Pharma Ireland Ltd |
SAMIDORPHAN (ALKS 33) IN COMBINATION WITH BUPRENORPHINE FOR THE TREATMENT OF DEPRESSIVE DISORDERS
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
RS61377B1
(sr)
|
2012-07-26 |
2021-02-26 |
Camurus Ab |
Opioidne formulacije
|
NZ716267A
(en)
|
2013-07-23 |
2017-05-26 |
Euro Celtique Sa |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
GB201516554D0
(en)
*
|
2015-09-18 |
2015-11-04 |
Camurus Ab |
Controlled-release formulations
|
BR112018072539A2
(pt)
|
2016-05-05 |
2019-03-26 |
Aquestive Therapeutics, Inc. |
composições de epinefrina de administração aumentada
|
US11273131B2
(en)
|
2016-05-05 |
2022-03-15 |
Aquestive Therapeutics, Inc. |
Pharmaceutical compositions with enhanced permeation
|